Creso Pharma

📋 About: Creso Pharma (ASX: CPH) is Medical cannabis and psychedelics company, developing therapeutic, nutraceutical and lifestyle products for human and animal health.

🌏 Macro Theme: World regulations are expected to open up as cannabis and psychedlics become an accepted form of alternative medicine.

Creso Pharma Company Milestones

✅ $9M Cap Raise @ 2.9c
✅ Convertible Notes Extinguished
✅ Key Appointment: Bruce Linton
✅ Next Investors Watchlist
✅ Improved Global Regulatory Environment for Cannabis
🌏 TGA Reclassifies Cannabis as a Schedule 4 drug
🌏 MORE Act Passed in the US
✅ $18M Cap Raise @19c per share
⚔️ MindMed NASDAQ Listing,(2)
✅ OTC Listing
🔲 Improved Global Regulatory Environment for Psychedelics
✅ [Unexpected News 1] Merger Announced with Red Light Holland
ℹ️ Red Light Holland Merger Terminated
🔲 [NEW] NASDAQ Listing
✅ [NEW] Key Management Appointment
🔲 [NEW] New (US) CEO Appointed
✅ [Unexpected News 2] Record Quarterly Revenue
🔲 Unexpected Positive Announcement 3
🔲 Next Investors Portfolio Launch?

Cannabis Products

Purchase orders listed here are over $150k only

✅ Purchase Order 1 $295K (Nutraceutical / Pharma Products)
✅ Purchase Order(s) 2 $415K + (Nutraceutical / Pharma Products)
✅ Purchase Order 3 $300K + (Nutraceutical / Pharma Products)
✅ Purchase Order 4 $247K + (Nutraceutical / Pharma Products)
✅ Purchase Order 5 $337K (Nutraceutical / Pharma Products)
🔲 Purchase Order 6 (Nutraceutical / Pharma Products)
🔲 Purchase Order 7 (Nutraceutical / Pharma Products)
🔲 Purchase Order 8 (Nutraceutical / Pharma Products)
✅ Purchase Order 1 $242K+ (Mernova Cannabis)
✅ Purchase Order(s) 2 $502K+ (Mernova Cannabis)
✅ Purchase Order 3 $177K+ (Mernova Cannabis)
✅ Purchase Order 4 $240K+ (Mernova Cannabis)
🔲 Purchase Order 5 (Mernova Cannabis)
🔲 Purchase Order 6 (Mernova Cannabis)
🔲 Purchase Order 7 (Mernova Cannabis)
🔲 Purchase Order 8 (Mernova Cannabis)

Psychedelics

✅ Plan to acquire Halucenex (psychedlics company) announced
✅ Increase Psilocybin Supply for Clinical Trials
✅ Halucenex receives Dealers License
✅ Complete Halucenex Acquisition
🔲 Phase II Clinical Trials recruitment
🔲 Phase II Clinical Trials begin
🔲 Phase II Clinical Trials - interim results
🔲 Phase II Clinical Trial Completed
🔲 Phase II Clinical Trial Results
🔲 Commercialisation milestone

Investment Plan

ASX:CPH is a medium term investment we hold and write about that is not currently in the portfolio. We took a position at 3c in October 2020 as a short term hold which upgraded to a medium hold after the company delivered. On March 26 2021 we increased our position at 19c. We are considering adding CPH to our long term portfolio if it can deliver a few more key milestones.

✅ Initial Investment @ 3c
✅ Increased Investment 19c
🔲 Increased Investment
✅ Price Increase 500% from Initial Entry
✅ Price Increase 1,000% from Initial Entry
🔲 Price Increase 2,000% from Initial Entry
🔲 12 Month Capital Gains Discount
✅ Free Carry
✅ Take Profits
🔲 Hold Remaining Position for Two Years

”Expected Company Milestones” are based on the company's publicly available execution plan and some assumptions made by our team on potential announcements that should de-risk the investment. “Our investment milestones” show our current long-term investment plan. Early stage investments are risky and there is no guarantee that the expected events will occur. The lists are not in sequential order.

Key

🔲 Expected Milestone
✅ Achieved Milestone
🟩 Above Average Result
🟨 Average (Expected) Result
🟧 Below Average Result
🟥 Negative Result
🌎 Macro Event
⚔️ Results from Other Company / Project
🔄 In Progress
[UPA] Unexpected Positive Announcement
[NEW] New Milestone Added